Home/Filings/4/0000899243-22-010333
4//SEC Filing

FRATTAROLI JOSEPH 4

Accession 0000899243-22-010333

CIK 0001750149other

Filed

Mar 8, 7:00 PM ET

Accepted

Mar 9, 8:22 PM ET

Size

6.1 KB

Accession

0000899243-22-010333

Insider Transaction Report

Form 4
Period: 2022-03-07
FRATTAROLI JOSEPH
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-03-07+62,50062,500 total
    Exercise: $1.07Exp: 2029-03-07Common Stock (62,500 underlying)
Holdings
  • Common Stock

    (indirect: By Flagship Consulting, Inc.)
    44,143
Footnotes (1)
  • [F1]One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date.

Issuer

Inhibikase Therapeutics, Inc.

CIK 0001750149

Entity typeother

Related Parties

1
  • filerCIK 0001272668

Filing Metadata

Form type
4
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 8:22 PM ET
Size
6.1 KB